Logo image of BTAI

BIOXCEL THERAPEUTICS INC (BTAI) Stock Fundamental Analysis

NASDAQ:BTAI - Nasdaq - US09075P2048 - Common Stock - Currency: USD

3.32  +0.35 (+11.78%)

After market: 3.37 +0.05 (+1.51%)

Fundamental Rating

1

BTAI gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 551 industry peers in the Biotechnology industry. BTAI may be in some trouble as it scores bad on both profitability and health. BTAI is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

BTAI had negative earnings in the past year.
In the past year BTAI has reported a negative cash flow from operations.
In the past 5 years BTAI always reported negative net income.
BTAI had a negative operating cash flow in each of the past 5 years.
BTAI Yearly Net Income VS EBIT VS OCF VS FCFBTAI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M

1.2 Ratios

BTAI has a Return On Assets of -103.88%. This is in the lower half of the industry: BTAI underperforms 76.77% of its industry peers.
Industry RankSector Rank
ROA -103.88%
ROE N/A
ROIC N/A
ROA(3y)-159.63%
ROA(5y)-112.19%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BTAI Yearly ROA, ROE, ROICBTAI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200 400 600

1.3 Margins

BTAI does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BTAI Yearly Profit, Operating, Gross MarginsBTAI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10K -20K -30K -40K

More info and screens

1

2. Health

2.1 Basic Checks

BTAI does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, BTAI has more shares outstanding
Compared to 5 years ago, BTAI has more shares outstanding
The debt/assets ratio for BTAI is higher compared to a year ago.
BTAI Yearly Shares OutstandingBTAI Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M
BTAI Yearly Total Debt VS Total AssetsBTAI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

BTAI has an Altman-Z score of -27.70. This is a bad value and indicates that BTAI is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -27.70, BTAI is not doing good in the industry: 88.38% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -27.7
ROIC/WACCN/A
WACC7.79%
BTAI Yearly LT Debt VS Equity VS FCFBTAI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M

2.3 Liquidity

BTAI has a Current Ratio of 1.48. This is a normal value and indicates that BTAI is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 1.48, BTAI is doing worse than 81.85% of the companies in the same industry.
A Quick Ratio of 1.45 indicates that BTAI should not have too much problems paying its short term obligations.
The Quick ratio of BTAI (1.45) is worse than 81.31% of its industry peers.
Industry RankSector Rank
Current Ratio 1.48
Quick Ratio 1.45
BTAI Yearly Current Assets VS Current LiabilitesBTAI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 83.65% over the past year.
Looking at the last year, BTAI shows a small growth in Revenue. The Revenue has grown by 5.35% in the last year.
EPS 1Y (TTM)83.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%89.22%
Revenue 1Y (TTM)5.35%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-71.13%

3.2 Future

BTAI is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 15.22% yearly.
Based on estimates for the next years, BTAI will show a very strong growth in Revenue. The Revenue will grow by 151.92% on average per year.
EPS Next Y73%
EPS Next 2Y33.14%
EPS Next 3Y26.54%
EPS Next 5Y15.22%
Revenue Next Year-49.13%
Revenue Next 2Y47.57%
Revenue Next 3Y200.07%
Revenue Next 5Y151.92%

3.3 Evolution

BTAI Yearly Revenue VS EstimatesBTAI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 50M 100M 150M 200M 250M
BTAI Yearly EPS VS EstimatesBTAI Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -20 -40 -60 -80

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

BTAI reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year BTAI is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BTAI Price Earnings VS Forward Price EarningsBTAI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BTAI Per share dataBTAI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -5 -10

4.3 Compensation for Growth

BTAI's earnings are expected to grow with 26.54% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y33.14%
EPS Next 3Y26.54%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for BTAI!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BIOXCEL THERAPEUTICS INC

NASDAQ:BTAI (8/6/2025, 8:11:18 PM)

After market: 3.37 +0.05 (+1.51%)

3.32

+0.35 (+11.78%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-04 2025-08-04
Earnings (Next)11-12 2025-11-12
Inst Owners11.02%
Inst Owner Change0%
Ins Owners0.76%
Ins Owner Change12.65%
Market Cap20.12M
Analysts76.67
Price Target16.83 (406.93%)
Short Float %6.37%
Short Ratio0.92
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)61.72%
Min EPS beat(2)45.53%
Max EPS beat(2)77.91%
EPS beat(4)4
Avg EPS beat(4)59.13%
Min EPS beat(4)42.08%
Max EPS beat(4)77.91%
EPS beat(8)5
Avg EPS beat(8)25.09%
EPS beat(12)5
Avg EPS beat(12)11.68%
EPS beat(16)8
Avg EPS beat(16)10.75%
Revenue beat(2)0
Avg Revenue beat(2)-55.31%
Min Revenue beat(2)-61.4%
Max Revenue beat(2)-49.22%
Revenue beat(4)1
Avg Revenue beat(4)-38%
Min Revenue beat(4)-83.93%
Max Revenue beat(4)42.56%
Revenue beat(8)2
Avg Revenue beat(8)-28.48%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-45.98%
PT rev (3m)-65.82%
EPS NQ rev (1m)7.1%
EPS NQ rev (3m)35.38%
EPS NY rev (1m)18.4%
EPS NY rev (3m)65.06%
Revenue NQ rev (1m)-10.18%
Revenue NQ rev (3m)-59.82%
Revenue NY rev (1m)-39.5%
Revenue NY rev (3m)-54.93%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 10.86
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-13.55
EYN/A
EPS(NY)-5.91
Fwd EYN/A
FCF(TTM)-10.95
FCFYN/A
OCF(TTM)-10.95
OCFYN/A
SpS0.31
BVpS-14.88
TBVpS-14.88
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -103.88%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-159.63%
ROA(5y)-112.19%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.05
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.48
Quick Ratio 1.45
Altman-Z -27.7
F-Score2
WACC7.79%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)83.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%89.22%
EPS Next Y73%
EPS Next 2Y33.14%
EPS Next 3Y26.54%
EPS Next 5Y15.22%
Revenue 1Y (TTM)5.35%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-71.13%
Revenue Next Year-49.13%
Revenue Next 2Y47.57%
Revenue Next 3Y200.07%
Revenue Next 5Y151.92%
EBIT growth 1Y63.91%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year39.13%
EBIT Next 3Y17.03%
EBIT Next 5Y20.3%
FCF growth 1Y57.27%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y57.26%
OCF growth 3YN/A
OCF growth 5YN/A